

# Special Issue

## Genomic and Molecular Profiling in Genitourinary Oncology: Shaping the Future of Diagnosis and Treatment

### Message from the Guest Editors

Recent advances in genomic and molecular profiling have revolutionized our understanding of genito-urinary malignancies, identifying distinct molecular subtypes, actionable mutations and predictive biomarkers that are reshaping diagnostic and therapeutic paradigms. The integration of next-generation sequencing, transcriptomic and proteomic analyses and liquid biopsy technologies has provided new insights into tumor evolution, resistance mechanisms and the tumor microenvironment. However, significant challenges remain, including intra-tumoral heterogeneity, evolving resistance mechanisms and the translation of molecular findings into clinically actionable approaches.

This Special Issue invites original research articles, reviews and perspectives focusing on how molecular insights are transforming the current and emerging therapeutic landscape in genito-urinary oncology. We welcome studies addressing molecular classification, novel biomarkers of prognosis or treatment response, mechanisms of resistance and translational strategies that connect and interface laboratory findings to clinical practice and advance precision oncology.

### Guest Editors

#### Dr. Ricardo Fernandes

1. Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5W9, Canada
2. Medical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre, Western University, London, ON N6A 3K7, Canada

#### Dr. Lilian Hanna

Department of Oncology, Schulich School of Medicine & Dentistry, Western University, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada



## Current Oncology

an Open Access Journal  
by MDPI

Impact Factor 3.4

CiteScore 4.9

Indexed in PubMed



[mdpi.com/si/260937](https://mdpi.com/si/260937)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/  
curroncol](https://mdpi.com/journal/curroncol)



### Deadline for manuscript submissions

31 October 2026



# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed

---



[mdpi.com/journal/  
curroncol](http://mdpi.com/journal/curroncol)

## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)

